Arvinas’ PROTAC halves protein suspected to play role in Parkinson’s
A first-in-human trial of Arvinas’ investigational Parkinson’s’ disease therapy, ARV-102, has been able to demonstrate a drop in the multifunctional…
All articles by Joshua Silverwood
Joshua Silverwood
-
-
Lundbeck’s superagonist prompts 61.2% seizure reduction
Lundbeck’s receptor superagonist designed to treat seizures associated with developmental and epileptic encephalopathies (DEEs) has seen a 61.2% reduction in total…
-
BeiGene halts ociperlimab amid poor Phase III trial predictions
California-based biotech BeiGene has terminated the clinical development programme for its lung cancer therapy ociperlimab, after an independent committee ruled…
-
Roche’s high-dose Ocrevus fails primary endpoint in MS trial
Roche’s Phase III trial examining higher doses of intravenous (IV) Ocrevus (ocrelizumab) as a means of slowing disability progression in…
-
Desentum to advance pollen allergy vaccine after positive Phase I trial
A vaccine designed to ward against allergic reactions brought on by birch pollen has proven to be safe and well-tolerated…
-
Compass’s tovecimig meets primary endpoint in Phase II/III BTC trial
Compass Therapeutics has announced top-line data from its COMPANION-002 trial investigating tovecimig, an antibody-based therapeutic for biliary tract cancer (BTC).…
-
Tenaya highlights HCM gene therapy interim data at ACC 2025
Three patients living with objectively severe heart disease have had their limitations on physical activity lifted following a single dose…
-
AstraZeneca’s AZD0780 cuts LDL-C by 50% in Phase IIb trial
AstraZeneca's AZD0780 has demonstrated significant efficacy in a Phase IIb trial, showing a 50.7% reduction in LDL-C after 12 weeks…
-
Cleerly CONFIRM2 study finds women with CAD at higher risk of MACE
Cleerly has announced interim results from a trial, described as the largest-ever cardiovascular phenotype outcomes study, finding that women living…
-
Transcend’s PTSD therapy shows potential in Phase II trial
Transcend Therapeutics’ Phase II IMPACT-1 study examining its neuroplastigen treatment for post-traumatic stress disorder (PTSD), dubbed TSND-201, has met its…
